<DOC>
	<DOCNO>NCT01406301</DOCNO>
	<brief_summary>Fondaparinux , synthetic specific factor Xa inhibitor , grant ACS indication Health Canada March 2007 EMEA September 2007 . Among ACS patient , fondaparinux indicate treatment UA/NSTEMI patient urgent PCI ( within 2 hour ) indicate , treatment STEMI patient manage thrombolytic initially receive form reperfusion therapy . The approved prescribing information fondaparinux ACS provide recommendation use patient undergoing PCI . The purpose study evaluate physician adherence prescribe information ACS patient treat fondaparinux undergo PCI . The primary endpoint proportion patient ACS treat fondaparinux , prescribe information PCI follow ( i.e. , adjunctive anticoagulant therapy administer time PCI ) . Measurement effectiveness safety fondaparinux use ACS patient within scope study . ARIXTRAÂ® trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>Fondaparinux EU-RMP ( Adherence )</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Discharge diagnosis ACS ( UA/NSTEMI STEMI ) PCI hospitalization Anticoagulant treatment fondaparinux Enrollment time index hospitalization clinical study could influence ACS treatment practice , specifically inhospital use anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>prescribe information</keyword>
</DOC>